NEW YORK (360Dx) – Beckman Coulter, a Danaher company, today announced that the US Food and Drug Administration has granted 510(k) clearance for its Early Sepsis Indicator — a hematology-based cellular biomarker to help emergency department physicians identify patients that have sepsis or are at increased risk of developing sepsis.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.